
Opinion|Videos|May 1, 2024
New Therapeutic Frontiers in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What new therapeutic options have emerged in the pulmonary arterial hypertension (PAH) treatment landscape, and what are their mechanisms of action and potential benefits?
- How do emerging therapies address the unmet needs in PAH management, such as improving symptom control, slowing disease progression, or targeting specific pathways?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Integrating Sotatercept Into PAH Care: Vallerie McLaughlin, MD
3
Eosinophilia Linked With Immune-Related Adverse Events in NSCLC Treatment
4
Efficacy and Equity With Oral PCSK9s: Ann Marie Navar, MD, PhD
5















































